Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study

期刊论文
出版模式：

开放获取
发表日期：

2024年9月8日

查看全文

Florens Lohrmann,
Androulla Efstratiou,
Uffe B. Skov Sørensen,
Roberta Creti,
Antoaneta Decheva,
Pavla Křížová,
Jana Kozáková,
Javier Rodriguez-Granger,
Manuel De La Rosa Fraile,
Immaculada Margarit,
Daniela Rinaudo,
Domenico Maione,
John Telford,
Graziella Orefici,
Mogens Kilian,
Baharak Afshar,
Pierrette Melin,
Reinhard Berner,
Markus Hufnagel,
Mirjam Kunze,
K Poulsen,
L Karstens,
L Baldassarri,
F Rigat,
A Berardi,
M Imperi

摘要

Introduction

Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD).

Methods

Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods.

Results

Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised ~ 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity.

Conclusions

Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.